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•Hourly variation of 83 pharmaceuticals in WWTP influent and effluent is presented. 
•Pharmaceuticals belonging to different therapeutic classes were analysed. 
•Some pharmaceuticals were detected in the influents in the μg/L range. 
•The importance of the determination of metabolites and transformation products is 
highlighted. 
Abstract 
The removal efficiency of pharmaceuticals in wastewater treatment plants (WWTPs) is 
variable and some of these compounds pass these plants almost intact and others 
presenting a removal efficiency close to 100%. Their incomplete removal results in a 
continuous discharge of pharmaceuticals into the environment. To assess the profile of 
contamination of influents and effluents over a day, a set of 83 pharmaceuticals were 
evaluated hourly in a WWTP in Leiria, Portugal. The composite samples of the influent 
and effluent were also collected. 
Concentrations varied from <MDL for ketoprofen, clarithromycin, ofloxacin, and 
diltiazem to 63.97 μg/L for caffeine in the WWTP influent composite sample and <MDL 
for clarithromycin, bupropion, and diltiazem to 2.01 μg/L for O-desmethylvenlafaxine for 
effluent composite sample. Concentrations in the range of μg/L were found for 
hydroxyibuprofen, salicylic acid, d,l-norephedrine, and caffeine in the WWTP influent, 
and diclofenac, carbamazepine, O-desmethylvenlafaxine in the WWTP effluents. 
For the samples collected hourly, thirty-eight and twenty-nine pharmaceuticals were 
detected in at least one WWTP sample. In the WWTP influent the total concentration of 
detected pharmaceuticals was higher between 15 and 22 h and lower in the period from 
23 to 10 h in the morning. In the WWTP effluent, a slight variation was noticed 
throughout the sampling hours. 
Carbamazepine, fluoxetine, sertraline, atorvastatin, caffeine, simvastatin, and trazodone 
were the pharmaceuticals with risk quotient (RQ) >1 in WWTP influents, and 
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1. Introduction 
Modern societies have benefited from the introduction of thousands of synthetic 
chemicals in the last century. However, the importance of their environmental fate has 
only been recognized in the last few decades, particularly in the case of micropollutants, 
such as pharmaceutical compounds (Rivera-Utrilla et al., 2013). 
Little is known about the possible ecological risks of most of these pollutants. This lack 
of knowledge results in a substantial amount of ongoing efforts to develop data and 
approaches that may be useful in assessing the impact of pharmaceuticals on the 
environment (Ankley et al., 2007). The assessment of their presence in the aquatic 
environment, at very low levels (ng/L), has been possible due to the developments in 
analytical determination, such as the use of ultra-high performance liquid 
chromatography coupled to tandem mass spectrometry detection (UHPLC-MS/MS) 
(Paíga et al., 2015; Paíga et al., 2016; Petrovic et al., 2010). This method proved to be a 
robust and reliable instrument for monitoring pharmaceuticals in environmental samples 
(Paíga et al., 2016). 
The massive use of pharmaceuticals for both human and veterinary purposes leads to the 
introduction of tons of these compounds in wastewaters, which is mainly attributed to the 
effluents of manufacturing processes, human and animal excretion, disposal of unused or 
expired pharmaceutical products, and unintentional shed through the manufacturing or 
distribution process (Diaz-Cruz et al., 2003). 
After treatment in wastewater treatment plants (WWTPs), considerable amounts can be 
transferred to surface waters either due to insufficient removal efficiencies or, if high 
removals are attained, concentrations up to ng/L and μg/L can still be found, depending 
on the compounds' mass loadings (Paíga et al., 2015; Rivera-Utrilla et al., 2013). 
Although it is not legally required in Europe, the control of this type of substances in 
surface waters is crucial, because it may affect water quality and potentially impact 
drinking water supplies, ecosystems, and human health (EU_L78/40, 2015). 
Outcomes of different studies showed that the concentrations of some pharmaceutical 
substances in wastewater and their treated effluents might fluctuate along the year 
(Fernández et al., 2014; Gago-Ferrero et al., 2017; Golovko et al., 2014; Vatovec et al., 
2016). In Portugal, this fluctuation is coherent with the existent statistical data that refers 
a monthly sales variation of pharmacotherapeutic subgroups (INFARMED, 2018). The 
main reasons found for the seasonal variation of the presence of pharmaceuticals in 
wastewater were the changes in some substances/products consumption rate in response 
to each season characteristic diseases (respiratory infections, depression and allergies 
treatment drugs, etc.) (Gago-Ferrero et al., 2017; Golovko et al., 2014; Moreno-González 
et al., 2014; Sun et al., 2014; Vatovec et al., 2016), demographic characteristics 
(population age) associated or not with demographic mobility (areas strongly influenced 
by educational institutions, holyday period, tourism areas) (Moreno-González et al., 
2014; Pereira et al., 2015; Vatovec et al., 2016) and weather variation (abundance/lack of 
precipitation, temperature changes, per capita domestic water consumption), all 
influencing the dilution rate (Diaz-Cruz et al., 2003; Fernández et al., 2014; Sun et al., 
2014). 
Some seasonal conditions, such as long periods of sunlight exposure of the effluent during 
the treatment were also referred as a cause to the reduction of some substances susceptible 
to photodegradation (Gago-Ferrero et al., 2017; Moreno-González et al., 2014). In 
addition to seasonal oscillation, weekly fluctuations in the concentrations of 
pharmaceutical substances in water courses were observed in several sampling points, 
associated with the same behavior in WWTP effluents, that occurred mainly between the 
weekend and the rest of the week (Moreno-González et al., 2014). Furthermore, daily 
variations were also noticed for some pharmaceutical products in wastewater, associated 
with daily drug administration patterns (Coutu et al., 2013; Plósz et al., 2010). 
In a previous study, the occurrence of 33 pharmaceuticals and metabolites was evaluated 
along the Lis river (Leiria, Portugal) and in influents and effluents of two WWTPs located 
along the river (Paíga et al., 2016). In samples collected from August 2013 to June 2014, 
pharmaceuticals, such as ibuprofen, ketoprofen, carbamazepine and fluoxetine, and the 
metabolite salicylic acid showed 100% of detection frequency, at levels up to 1.3 μg/L 
for ibuprofen (Paíga et al., 2016). 
The purpose of this study was to extend the number of pharmaceutical compounds 
analysed, using a new sampling campaign that took place in June 2017. Samples of one 
WWTP (Leiria, Portugal) influent and effluent were collected hourly, for 24 h. Effluent 
samples were collected considering the WWTP hydraulic retention time. Flow 
proportional 24-h composite samples of the influent and the effluent were also collected. 
A set of 83 pharmaceuticals belonging to different therapeutic classes, including non-
steroidal anti-inflammatory drugs (NSAIDs), analgesics, antibiotics, anorectics, 
anxiolytics, beta-blockers, laxatives, antidiabetic drug, antipsychotic, calcium channel 
blocker, fibrate lipid lowering agent, stimulants, lipid regulator and cholesterol lowering 
statin drugs, proton pump inhibitor, and psychiatric drugs were assessed. The variation 
throughout the day of pharmaceutical concentrations, and the removal efficiency of the 
WWTP were characterized. 
2. Materials and methods 
2.1. Sampling site and sample collection 
Leiria is a city and a municipality in the Centre Region of Portugal. Lis river is one of 
Leiria's most important resources. Almost 40 km long, the river drains in Vieira beach, 
after crossing the Lis fields, a wide farming area watered by its abundant flow (Vieira et 
al., 2012). Nowadays, after an extensive requalification project as part of the POLIS 
Programme, the riverbanks are the chosen place to exercise and play sports. Lis River 
also constitutes an important inland water resource for domestic, industrial and irrigation 
purposes (LeiriaMunicipality, 2018), thus it is imperative to prevent and control water 
pollution. 
Hog farming located along the basin of the Lis river is known for being one of the sources 
of pollution in the river (Vieira et al., 2012). According to the news, Lis river basin has 
been subjected in the past 30 years to constant ecological disasters, mainly due to piggery 
untreated wastewater discharges (Vieira et al., 2012). Freshwater pollution problems are 
gaining attention regionally due to their social, economic, and health impacts. Moreover, 
the sources of contamination may be influenced by different geographical patterns of 
pharmaceuticals consumption (Vieira et al., 2012), and important fluctuations due to 
seasonal variations might also occur (Paíga et al., 2016). 
The influents and effluents of a WWTP located along the Lis river are target of the present 
study. The wastewaters treated by the Coimbrão WWTP are domestic and hospital 
wastewaters, and landfill leachate. The WWTP also treats animal farming sewage (pigs 
manure), through the sludge treatment process, since the manure is discharged by trucks 
on the WWTP, going directly to anaerobic digesters, where that slurry joins the sludge 
removed from the liquid phase in the treatment process. The WWTP comprises primary, 
secondary (activated sludge), and tertiary (disinfection achieved by UV exposure) 
treatments. This WWTP is in operation since 2008 and has the capacity to treat about 
37,997 m3 of wastewater per day, corresponding to 248,685 inhabitants (Paíga et al., 
2016). Of the total capacity volume, nearly 80% are domestic. The remaining volumes 
come mainly from industries and around 5% are swine effluent from farms located in the 
immediate vicinity of the WWTP. At the end of treatment, a portion of the treated effluent 
is reused for irrigation of the WWTP's green spaces and for washes and the other parcel 
is directly discharged to the Lis river (Website, 2015). The hydraulic retention time and 
the sludge retention time are 25 h and 18 d, respectively. 
Influents and effluents were collected each hour, during a 24 h cycle, and a composite 
sample from 24 h was also analysed. Effluent samples were collected considering the 
WWTP hydraulic retention time. Polypropylene bottles (1 L) pre-rinsed with ultrapure 
water were used for the sample collection. Samples were kept at 4 °C until arrival to the 
laboratory. Then, the samples were vacuum filtered through 0.45 μm nylon membrane 
filters (Fioroni Filters, Ingré, France) and stored at −20 °C until extraction. 
2.2. Reagents, solvents and materials 
Methanol LC-MS and acetonitrile LC-MS grade were supplied by Scharlau (Barcelona, 
Spain), propanol LC-MS was obtained from Sigma-Aldrich (Steinheim, Germany), and 
formic acid (PA-ACS) and hydrochloric acid (HCl) 37% were supplied by Carlo Erba 
(Rodano, Italy). Ultrapure water (resistivity of 18.2 MΩ.cm) was produced using a 
Simplicity 185 system (Millipore, Molsheim, France). 
Ethylenediaminetetraacetic acid disodium salt 2-hydrate (Na2EDTA) (assay > 99.0%) 
was obtained from Panreac (Barcelona, Spain). 
Pharmaceuticals, transformation products, metabolites, isotopically labelled internal 
standards (ILIS), CAS, molecular weight, formula, and supplier company are presented 
in Table SM1 (Supplementary material). All compounds were of high purity grade 
(≥98%). 
Individual stock standard and ILIS solutions were prepared at a concentration of 
1000 mg/L on a weight basis. Different solvents or mixture of solvents were used: 
acetonitrile, methanol, acetonitrile:methanol (1:1, v/v), acetonitrile:5% acetic acid in 
ultrapure water, methanol: ultrapure water (1:1, 2:1, v/v), and ultrapure water:10% acetic 
acid in ultrapure water (1:1, v/v) (Barry et al., 2004; Paíga et al., 2017a, Paíga et al., 
2017b) (Table SM1, Supplementary material). All stock solutions were stored at −20 °C. 
Working standard solutions, containing all pharmaceuticals were prepared in 
acetonitrile:ultrapure water (30:70, v/v). A mixture with the seventeen ILIS was also 
prepared to be used for internal standard calibration. 
Caffeine 13C3 (1000 mg/L), carbamazepine-d10 (100 mg/L), O-desmethylvenlafaxine 
(100 mg/L), diazepam-d5 (1000 mg/L), norsertraline hydrochloride (100 mg/L), 
sibutramine hydrochloride (1000 mg/L), topiramate-d12 (100 mg/L), and venlafaxine-d6 
(100 mg/L) were purchased as methanolic solutions. 
All chromatographic solvents were filtered through a 0.22 μm nylon membrane filter 
(Fioroni Filters, Ingré, France) using a vacuum pump (Dinko D-95, Barcelona, Spain). 
The solvents were degassed for 15 min in an ultrasonic bath (Sonorex Digital 10P, 
Bandelin DK 255P, Germany). SPE cartridges Strata-X (200 mg, 3 mL) from 
Phenomenex, Inc. (California, USA) were used in the SPE extraction. Sample extracts 
were filtered through 0.22 μm PTFE syringe filters (Specanalitica, Carcavelos, Portugal) 
before the chromatographic analysis. 
2.3. Sample extraction 
In the previous work of the authors (Paíga et al., 2015, Paíga et al., 2016) SPE procedure 
was optimized for the extraction of 33 pharmaceuticals belonging to the 
NSAIDs/analgesics, antibiotics, and psychiatric drugs. The optimized procedure was then 
extended for the extraction of 83 pharmaceuticals. In brief, SPE cartridges were 
conditioned and equilibrated with 5 mL of methanol, 5 mL of ultrapure water followed 
by 5 mL of ultrapure water at pH 2 using a vacuum system manifold (Chromabond, 
Düren, Germany). Chelating agent was added to the filtered samples. A suitable volume 
of a 0.1 M Na2EDTA solution was added to the samples to achieve a final concentration 
of 0.1% (g solute/g solution). Volumes of 100 mL for the WWTP effluent and 50 mL for 
the WWTP influent samples were used, adjusted to pH 2 with concentrated HCl, and pre-
concentrated on Strata-X cartridges. The cartridges were then rinsed with 5 mL 
(2 × 2.5 mL) of ultrapure water and dried under vacuum for 60 min to remove excess 
water. Then, a total of 10 mL of methanol (4 × 2.5 mL) were used in the elution step and 
the extracts were evaporated under a gentle stream of nitrogen. The residues were 
reconstituted with 500 μL of acetonitrile:ultrapure water (3:7, v/v) and 5 μL of a mixture 
of ILIS solutions was added. The final concentration of each ILIS in the standard solutions 
and in the WWTP effluents and influents samples is presented in Table SM2 
(Supplementary Material). 
2.4. UHPLC-MS/MS analysis 
Chromatographic analysis was performed on a Shimadzu Nexera UHPLC system 
(Shimadzu Corporation, Kyoto, Japan) equipped with two solvent delivery pumps (LC-
30 AD), a column oven (CTO-20 AC), an auto-sampler (SIL-30 AC), a degasser (DGU-
20A 5R), and a system controller module (CBM-20A) coupled to a triple-quadrupole 
mass spectrometer (Ultra-Fast Mass Spectrometry series LCMS-8030, Shimadzu 
Corporation, Kyoto, Japan) operated in the electrospray ionization (ESI) mode. Lab 
Solutions software (Shimadzu Corporation, Kyoto, Japan) was used for control and data 
processing. 
Kinetex™ C18 column (2.6 × 150 mm i.d.; 1.7 μm particle size) from Phenomenex, Inc. 
(California, USA) and Cortecs™ UPLC® C18+ column (100 × 2.1 mm i.d.; 1.6 μm 
particle size) from Waters (Milford, Massachusetts, USA) were the two columns used for 
the chromatographic separation. 
From the preceding works of the authors, chromatographic separation, chromatographic 
columns, different mobile phases, mode of elution (isocratic or gradient), oven 
temperature, and flow rate were tested. The optimized programs were developed for 
NSAIDs/analgesics, antibiotics, psychiatric drugs (Paíga et al., 2017b) and anorectic, 
antiepileptic, anxiolytics, laxatives, and stimulants compounds (Paíga et al., 2017a). 
32 new pharmaceuticals were added to the present study belonging to the therapeutic 
classes of antibiotics, antidiabetic drug, antipsychotic, calcium channel blocker, β-
blockers, fibrate lipid lowering agent, lipid regulator and cholesterol lowering statin 
drugs, proton pump inhibitor, psychiatric drugs metabolites, and stimulant compounds. 
Thus, a total of 83 pharmaceuticals were analysed. Ampicillin, atorvastatin, atenolol, 
caffeine, chlortetracycline, chlorpromazine, citalopram N-oxide, didemethylcitalopram, 
demethylcitalopram, O-desmethylvenlafaxine, diltiazem, doxycycline, erythromycin, 
fenofibrate, lansoprazole, lomefloxacin, metformin, moxifloxacin, norfloxacin, 
oxytetracycline, propranolol, prulifloxacin, simvastatin, sulfathiazole, sulfamethizole, 
sulfaquinoxaline, and tetracycline were analysed in the positive ESI mode (Paíga et al., 
2017b) using a Cortecs™ UPLC® C18+ column. Amoxicillin, citalopram propionic acid, 
gemfibrozil, pravastatin, and potassium clavulanate, ionized in negative ESI, were 
introduced in the program developed for the analysis of pharmaceutical adulterants in 
plant food supplements (Paíga et al., 2017a) using a Kinetex™ C18 column. 
The pharmaceuticals analysed in each program are described in Table SM3 
(Supplementary material) and all chromatographic conditions and MS parameters are 
presented in Table SM4 (Supplementary material). Most of the pharmaceuticals have a 
good peak shape except for tetracycline group that show tailing. Ampicillin, amoxicillin, 
atenolol, chlorocycline, ephedrine, lomefloxacin, oxytetracycline, potassium clavulanate, 
pravastatin, propranolol, and tetracycline showed a lower sensitivity when compared with 
the remaining pharmaceuticals. 
An overlay chromatogram of the studied pharmaceuticals in each program is presented in 
Fig. SM1 (Supplementary material). In program II, a large number of pharmaceuticals 
(50) is analysed making it difficult to view the peaks in the chromatogram. Therefore, in 
Fig. SM1 (Supplementary Material) three chromatograms for program II are presented in 
Fig. SM1 (Supplementary material) with a legend of b), c), and d). The antibiotic and 
psychiatric drugs, two families already studied by the authors in previous studies (Paíga 
et al., 2017b; Paíga et al., 2016), are shown in the chromatograms b) and c) and the new 
pharmaceuticals inserted in program II are presented in the chromatogram d) (Fig. SM1, 
Supplementary material). 
The mass spectrometer was operated in multiple reaction monitoring mode (MRM) and 
two MRM transitions were monitored for each compound, being the most intense used as 
quantifier and the second one as qualifier. For the new pharmaceuticals, MRM settings 
were analyte-specific and were optimized by direct injection of individual standard 
solutions with a concentration of 100 mg/L. Optimized mass spectrometry parameters 
(precursor ions, quantifier and qualifier ions, and ion ratio), the optimum collision 
energies and cone voltages selected for each transition used for quantification and 
identification of each pharmaceutical are shown in Table SM5 (Supplementary material). 
The auto-sampler was operated at 4 °C and the needle was rinsed before and after sample 
aspiration using acetonitrile:methanol:propanol (1:1:1, v/v/v). The injection volume was 
5 μL and column oven was set at 30 °C. Argon was used as the collision induced 
dissociation gas (CID) at a pressure of 230 kPa. 
2.5. Validation of the analytical method 
A thorough and complete method validation of the studied compounds in WWTP 
influents and effluents was performed. The method was validated for linearity, method 
detection limits (MDLs), method quantification limits (MQLs), precision (intra- and 
inter-day), recovery, and matrix effect (ME). 
The linearity of the method was established by setting calibration curves using linear 
regression analysis with twelve concentration levels in the range of 0.5 to 1000 μg/L (0.5, 
1.0, 5.0, 10, 25, 50, 75, 100, 250, 500, 750, and 1000 μg/L). Solvent blanks containing 
acetonitrile were prepared to run after every ten samples for monitoring the instrumental 
background. 
MDLs and MQLs were determined as the minimum amount detectable of analyte with a 
signal-to-noise ratio of 3 and 10, respectively. 
Method precision was determined by repeated intra- and inter-day analysis and expressed 
as the relative standard deviation (RSD (%)). A standard mixture containing all the 
analytes at a final concentration of 50, 100, and 250 μg/L was used and six successive 
injections in one day and sextuplicate injections in three consecutive days were 
performed, respectively. 
The influence of the ME was evaluated by the comparison of the matrix matched 
calibration curve and the calibration curve prepared in solvent, namely, 
acetonitrile:ultrapure water (30:70, v/v). For each compound, the ratio between its 
response in the wastewater effluents and influents and the response of the standard in 
solvent at the same concentration (250 μg/L) was taken as ME, and was calculated 
according to the Eq. (1) (Gros et al., 2012). A value of zero indicates that there is no ME, 
while for a positive value there is an ion enhancement signal and a negative % value 
indicates an ion suppression signal.(1) 
Recovery was calculated by comparing the MRM peak area for samples spiked prior to 
SPE extraction (pre-spiked sample) with the MRM peak area for samples spiked after 
SPE extraction (post-spiked sample). Thus, for the WWTP influents and effluents a blank 
and a fortified experiment were carried out for the pre- and post-spiked sample. The 
pharmaceuticals extraction efficiencies were determined by analysis of three replicates 
with the following conditions for WWTP influent: 
Level I (0.5 μgpharmaceutical/Lsample): 1 mL of 25 μg/L of fortified concentration using 50 mL 
of sample; 
Level II (1.0 μgpharmaceutical/Lsample): 1 mL of 50 μg/L of fortified concentration using 50 mL 
of sample; 
Level III (2.5 μgpharmaceutical/Lsample): 1 mL of 125 μg/L of fortified concentration using 
50 mL of sample; 
and for WWTP effluents: 
Level I (0.25 μgpharmaceutical/Lsample): 1 mL of 25 μg/L of fortified concentration using 
100 mL of sample; 
Level II (0.5 μgpharmaceutical/Lsample): 1 mL of 50 μg/L of fortified concentration using 
100 mL of sample; 
Level III (1.25 μgpharmaceutical/Lsample): 1 mL of 125 μg/L of fortified concentration using 
100 mL of sample. 
2.6. Environmental risk characterization 
The risk that the pharmaceuticals detected in the WWTP influents and effluents in the 
present study may represent to the aquatic environment was estimated through their risk 
quotient (RQ) at three representative trophic levels of the aquatic ecosystem (algae, 
daphnia, and fish). The RQ depends not only on the concentration of each pharmaceutical 
but also on its ecotoxicity (Ginebreda et al., 2010). The RQs are defined as the ratio of 
potential exposure to the substance and the level at which no adverse effects are expected. 
According to EU guidelines (EMEA, 2006) the RQ was calculated for each substance 
according to the Eq. (2):(2) 
where the MEC corresponds to the highest concentration of the pharmaceutical found in 
the analysed samples, while the PNEC was calculated dividing the lowest acute toxicity 
value (median effective or lethal concentration, EC50 or LC50) reported in the peer 
reviewed literature for the three selected trophic levels by the pertinent assessment factor 
(usually 1000) (EuropeanComission, 2003). ECOSAR predictive model (v1.11) 
(USEPA, 2012) was used for MEC/PNEC calculation. 
A worst-case scenario approach was followed, and the maximum measured 
environmental concentration found in the WWTP influents and effluents in the Lis river 
was used. When the compound was detected in the samples but the concentration was 
below the method quantification limit (MQL) or the method detection limit (MDL), half 
of the MQL was considered. 
The potential ecological risk of these chemicals was evaluated according to a frequently 
used risk ranking criterion (Rivera-Jaimes et al., 2018). If RQ is equal or above 1 there is 
a potential environmental risk, whereas for values lower than 1 it is not expected risk 
(Ginebreda et al., 2010). Moreover, Mendoza et al. (2015) mentioned that for RQ values 
between 0.1 and 1, a low or negligible risk can be expected, while for RQ values between 
1 and 10 a medium risk can be expected. RQ values above 10 indicate a high ecological 
risk (Mendoza et al., 2015). 
3. Results and discussion 
3.1. Method performance 
Following the European Union criteria of 2002 (2002/657/EC, 2002), the analytical 
methodology used was validated in terms of linearity, inter- and intra-day precision, 
recovery, sensitivity (MDL and MQL), and matrix effects. The obtained results have been 
summarized in Table 1 and discussed in the following paragraphs. 
Table 1. Retention time (min), linearity, recoveries (%) at three levels of fortification for 
WWTP influents and WWTP effluents for all pharmaceuticals grouped in each 
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CP-Chromatographic program. 
a 
Pharmaceuticals organized in the table by their retention time in each 
chromatographic program. 
b 
Retention time of diazepam-d5 is different in accordance with the 
chromatographic method used. 
Isotope-labelled standards were used as internal standards in order to improve the method 
precision, accuracy, and linearity (Maddela et al., 2017). However, ILIS are not always 
available or are very expensive. For the analysis and quantification of the 83 
pharmaceuticals of the present study, seventeen ILIS were selected. A mixture with all 
ILIS was added to the standards for the construction of the internal standard calibration 
curves for all pharmaceuticals and added to each sample extract (WWTP effluents and 
influents), respectively. 
As shown in Table 1 a slight difference in retention time between analytes and their 
corresponding ILIS was observed. All ILIS show a slightly earlier retention time when 
compared with the retention time of the analyte. Wang et al. (2007) demonstrated for the 
first time that a minimum difference in retention time between the analyte and the ILIS 
was caused by deuterium isotope effect (Wang et al., 2007). The phenomenon is 
explained due to the replacement of the carbon bound hydrogen with deuterium, which 
slightly alters the lipophilicity of the molecule, and hence the retention time of the 
deuterium labelled compound during reversed phase separations (isotope effect) (Wang 
et al., 2007). 
Twelve calibration points were used for the construction of the internal standard 
calibration curves. Linear regression analysis over the concentration ranges shown in 
Table 1 presented good fits (r2 ≥ 0.99). 
For the 83 pharmaceuticals, the validation of the chromatographic and SPE extraction 
methodologies developed (Paíga et al., 2017a, Paíga et al., 2017b) showed satisfactory 
performance in terms of repeatability (RSD below 10 and 15% for intra- and inter-day 
analyses), accuracy (62.7% and 63.9% of the 83 pharmaceuticals had recoveries above 
75% in WWTP effluents and WWTP influents (Fig. 1)), and sensitivity (the lowest limits 
were ≤0.1 and ≤0.2 ng/L for MDL and MQL for both matrices). Considering all the 
pharmaceuticals, mean MDL and MQL values were calculated. Thus, 5.51 and 34.7 ng/L 
for MDL, and 18.4 and 116 ng/L for MQL in WWTP effluents and influents matrices, 
respectively, was obtained. Higher limits were observed for ampicillin, caffeine, 
enrofloxacin, lansoprazole, moxifloxacin, d,l-norephedrine, norfloxacin, norsertraline, 
oxytetracycline, paroxetine, potassium clavulanate, pravastatin, simvastatin, and 
zonisamide in WWTP influents. Potassium clavulanate was the pharmaceutical with the 
highest MDL and MQL for both matrices. 
 
 
Fig. 1. Percentage of the pharmaceuticals obtained in each range of recovery in the WWTP effluent and influent 
samples. The present results refer to fortification at level III. 
The results obtained at three different spiking levels for the two types of WWTP samples 
are presented in Table 1, and a good consistency of the recoveries was obtained in the 
three levels of fortification for most of the pharmaceuticals. For the majority of the studied 
pharmaceuticals, RSDs lower than 10% were found. The exception was observed for 
compounds such as cathine, d,l-norephedrine, ephedrine, synephrine, and d,l-
methamphetamine, for which very low recoveries were also obtained, probably due to the 
higher hydrophilicity of these compounds. 
Lansoprazole was not detected in all spiking levels and potassium clavulanate, 
amoxicillin, zonisamide, pravastatin, topiramate, phenolphthalein, citalopram propionic 
acid, and gemfibrozil were not detected at the lower level for WWTP influent. For 
lansoprazole the non-detection could be attributed to the fact that the extraction conditions 
used were not the most appropriate to retain this pharmaceutical onto the sorbent. 
The good recoveries obtained using Strata-X and sample pH adjusted to 2 can be 
explained by the presence of acidic functional groups in the molecular structure of many 
pharmaceuticals. Therefore, lowering pH under their pKa values enhances the presence 
of neutral forms and their interaction with the reversed-phase sorbent. 
Pharmaceuticals were gathered in four groups, namely (i) recoveries lower than 25%, (ii) 
recoveries between 25 and 50%, (iii) recoveries between 50 and 75%, and (iv) recoveries 
higher than 75% (Fig. 1). The average recovery was around 74.9% and 76.9%, for WWTP 
effluents and influents, respectively. As already mentioned, most of the studied 
pharmaceuticals presented recoveries above 75% and the smallest percentage of the 
pharmaceuticals was allocated to recoveries <25% and between 25 and 50%. Recoveries 
lower than 25% were achieved for potassium clavulanate in WWTP effluent, and 
atenolol, lansoprazole, metformin, ephedrine, cathine, synephrine, and d,l-norephedrine 
for both WWTP effluent and WWTP influent samples. 
ME was evaluated for the two types of samples and results are presented in Figs. SM2 
and SM3 (Supplementary material). The bar graphs were constructed by grouping the 
pharmaceuticals into their therapeutic classes. The group named “others” includes several 
therapeutic classes with few pharmaceuticals. Pharmaceuticals ordering in the bar graphs 
was performed from the highest to the lowest ME value. So, it should be noted that both 
the legends of these two figures and the numbering of each bar is different. For almost all 
pharmaceuticals ME were observed, in the studied matrices, expressed as an ion 
suppression. Pharmaceuticals belonging to the NSAIDs and to the stimulant, anorectics, 
anxiolytics, and laxatives groups, for both WWTP influent and effluent matrices, showed 
ion suppression except for caffeine in WWTP influent. Ion suppression was also observed 
for most of the pharmaceuticals included in the antibiotics, psychiatric drugs, and 
“others”. A total of 11 out of 72 and 19 out of 64 pharmaceuticals had an ion enhancement 
signal for WWTP effluent and influent samples, respectively. 
Acetaminophen, erythromycin, and lansoprazole, had remarkable ion suppression, having 
lansoprazole the biggest ME in WWTP effluents. On the other hand, for WWTP influents, 
more pharmaceuticals showed pronounced ion suppression (carboxyibuprofen, naproxen, 
nimesulide, ketoprofen, acetylsalicylic acid, salicylic acid, potassium clavulanate, 
bupropion, metformin, and d,l-methamphetamine), most of which are included in the 
NSAIDs/analgesics classes. In the case of ion enhancement, the highest ME was observed 
for atenolol, propranolol, and azithromycin in WWTP effluent, and for ciprofloxacin, 
atenolol, propranolol, and caffeine in the WWTP influents. It should be noted that 
atenolol and propranolol showed an ion enhancement signal in both wastewaters matrices. 
Matrix effects in LC-MS/MS analysis are not easy to explain, from the chemical point of 
view, for a particular analyte. In a multi-residue method developed for a large number of 
compounds, with different physico-chemical properties, matrix effects will depend on the 
matrix composition (influent or effluent), the sample preparation method which will allow 
to eliminate several matrix components, while keeping others, the mobile phase and the 
ionization/detection conditions used. 
Regarding NSAIDs, ion suppression both in influents and effluents was found for all the 
compounds (Figs. SM2 and SM3, Supplementary Material). Acetaminophen presented 
the lowest signal suppression in influents but the highest signal suppression in effluents 
when compared with the remaining NSAIDs. For six out of ten compounds, namely: 
carboxyibuprofen, naproxen, nimesulide, ketoprofen, acetylsalicylic acid, and salicylic 
acid, ion suppression increased in influent samples when compared with effluent samples. 
As also reported in the work of Gracia-Lor et al. (2012) the higher complexity of the 
influents leads to strong matrix effects (commonly ionization suppression), which can 
hamper the detection of some analytes at very low levels. Signal suppression for the 
majority of the NSAIDs was also observed in previous works of the authors (Paíga et al., 
2016, Paíga et al., 2017b). 
Antibiotics exhibited signal enhancement in a few cases and mainly signal suppression 
(Figs. SM2 and SM3, Supplementary Material). For influent samples, matrix effects were 
found to be related to the antibiotic family. For example, fluoroquinolones were the 
antibiotics for which signal enhancement was found. Regarding the antibiotics showing 
signal suppression, the lowest value was observed for trimethoprim, followed by 
sulfonamides, macrolides, tetracyclines, and, finally, the B-lactam antibiotics. The 
highest signal suppression was found for potassium clavulanate. However, this pattern 
was not observed for the effluent samples, regardless of their less complex composition. 
In the case of psychiatric drugs, and for influent samples, the parent compound and the 
corresponding metabolite or metabolites appear together in the sequence, meaning that 
they have similar matrix values (Fig. SM3, Supplementary Material). This was also found 
for all the benzodiazepine pharmaceuticals. 
For the group “others”, six and three in eleven compounds had signal enhancement in 
influent and effluent samples, respectively. As verified for antibiotics and psychiatric 
drugs, the pharmaceuticals were also grouped by their chemical family. 
For caffeine an ion suppression signal was observed in the WWTP effluent and an ion 
enhancement signal for WWTP influent (Figs. SM2 and SM3, Supplementary material). 
3.2. Occurrence of pharmaceuticals in WWTP influents and effluents 
The effects of pharmaceuticals on aquatic ecosystems are the subject of increasing 
environmental concern (Richmond et al., 2016). The presence of pharmaceuticals in water 
may be associated with certain factors, including the pharmaceuticals' physicochemical 
properties that allow them to resist to biological, physical, and chemical processes 
(Brooks et al., 2005; Snyder, 2008), and are determinant for their behavior once 
introduced in the sewer system. The molecular weight, water solubility, partitioning 
values such as Log (Kow), which give an indication of the molecule's polarity, and pKa 
values will be decisive for their behavior together with the molecule stability. 
Generally, compounds with higher water solubility values, and that are not 
(bio)degradable, may present lower removal percentages. Conversely, less polar 
compounds, even when they are resistant to (bio)degradation may be removed in the 
biological treatment due to sorption to suspend solids (Peng et al., 2012). 
In the current study, pharmaceuticals were analysed in each WWTP sample, namely in 
grab samples (influent and effluent hourly collection, during one day) and in the 
composite WWTP (influent and effluent) samples. Regarding the composite samples, the 
concentration obtained for the detected pharmaceuticals is presented in Table SM6 
(Supplementary material). 
Results show that 25 and 20 pharmaceuticals were detected in the WWTP influent and 
effluent samples, respectively, most of them belonging to the NSAIDs/analgesic, 
antibiotics, and psychiatric drugs. In Table 2, the results of the present study are shown 
together with the results reported for the same pharmaceuticals in different countries in 
Europe (Afonso-Olivares et al., 2017; Aydin et al., 2017; Bahlmann et al., 2014; Baker 
and Kasprzyk-Hordern, 2013; Brunsch et al., 2018; Camacho-Muñoz et al., 2014; Evans 
et al., 2015; Gardner et al., 2013; Gracia-Lor et al., 2012; Kasprzyk-Hordern et al., 2009; 
Kasprzyk-Hordern et al., 2010; Kay et al., 2017; Kosma et al., 2014; Mendoza et al., 
2015; Muz et al., 2012; Nakada et al., 2017; Petrie et al., 2017; Ternes, 1998; Urtiaga et 
al., 2013; Vasskog et al., 2006; Verlicchi et al., 2012; Wick et al., 2009), America (Conn 
et al., 2006; Fang et al., 2012; Gerrity et al., 2011; Lajeunesse et al., 2008; Lajeunesse et 
al., 2012; Nelson et al., 2011; Rivera-Jaimes et al., 2018; Spongberg and Witter, 2008; 
Writer et al., 2013; Yu et al., 2013; Zacarías et al., 2017), Asia (Archana et al., 2017; 
Aydin et al., 2017; Behera et al., 2011; Chang et al., 2008; Hong et al., 2015; Muz et al., 
2012; Nguyen et al., 2018; Shraim et al., 2017; Subedi et al., 2017; Suzuki et al., 2014; 
Zhang et al., 2018; Zhou et al., 2010), Africa (Madikizela and Chimuka, 2017), and 
Australia (Cardenas et al., 2016; Roberts et al., 2016; Watkinson et al., 2007; Watkinson 
et al., 2009). 
Table 2. Measured concentrations (ng/L) for the target analytes in WWTP influent and 
effluent composite samples reported in this study and in the literature.
 









Portugal 683 (±4.1%) n.d. Present study 
Spain 2300–14,900  (Mendoza et al., 2015) 
Spain 330–165,000  
(Camacho-Muñoz et 
al., 2014) 
Italy 500–1200 12.0–58.0 (Verlicchi et al., 2012) 
Greece n.d.–65,402.8 n.d.–1060.3 (Kosma et al., 2014) 
UK 68,107–482,687 <80.0–24,525 
(Kasprzyk-Hordern et 
al., 2009) 
UK 171,875–512,813 692.0–2195 (Petrie et al., 2017) 
America 
México 2330–14,900 n.d. 
(Rivera-Jaimes et al., 
2018) 
Mexico 100–4300 100–1000 (Zacarías et al., 2017) 
Asia 
Vietnam 11,000–30,000 n.d.–<LOQ (Nguyen et al., 2018) 
Korea 843–7750  (Hong et al., 2015) 
China 739.9–8983.9 2.90–58.4 (Zhang et al., 2018) 
Saudi 
Arabia 
3610–99,600 <LOD–90.5 (Shraim et al., 2017) 
India <LOQ–30,000 <LOQ–11000 (Archana et al., 2017) 
India 2900–11,000 <LOQ–1200 (Subedi et al., 2017) 
Diclofenac Europe 
Portugal 449 (±6.6%) 1934 (±1.4%) Present study 
Spain 600–2500  (Mendoza et al., 2015) 






Spain 45.0–1605 n.d.–2240 
(Afonso-Olivares et 
al., 2017) 
Spain <LOD–1,67  
(Camacho-Muñoz et 
al., 2014) 
UK 239.9–1881 239.4–521.2 (Petrie et al., 2017) 
Italy 360–480 220–330 (Verlicchi et al., 2012) 
Greece n.d.–5164 n.d.–382.5 (Kosma et al., 2014) 
Germany  420–4880 (Brunsch et al., 2018) 
UK 57–1161 6.00–496 
(Kasprzyk-Hordern et 
al., 2009) 
UK 175–1805 401–2830 (Kay et al., 2017) 
America 
Mexico 560–2470 466–2180 
(Rivera-Jaimes et al., 
2018) 
USA  18.0–47.0 (Nelson et al., 2011) 
Asia 
Korea 12.0–113  (Hong et al., 2015) 
China 128.6–1027.1 7.9–237.7 (Zhang et al., 2018) 








Portugal 421 (±6.2%) 217 (±0.13%) Present study 
Spain 400–2800  (Mendoza et al., 2015) 
Spain 1150–56,300 21.0–21,700 
(Afonso-Olivares et 
al., 2017) 






Spain <LOD–220,000  
(Camacho-Muñoz et 
al., 2014) 
Italy 930–1200 10.0–120 (Verlicchi et al., 2012) 
Greece n.d–8890.1 n.d.–301.2 (Kosma et al., 2014) 
UK 968–6328 65.0–491 
(Kasprzyk-Hordern et 
al., 2009) 
UK 4016–20,215 1746–3718 (Petrie et al., 2017) 
UK 76–14,231 863–4617 (Kay et al., 2017) 
America Mexico 370–2835 n.d. 
(Rivera-Jaimes et al., 
2018) 
Asia 
Vietnam 780–1700 n.d.–<LOQ (Nguyen et al., 2018) 









Portugal <MDL 56.5 (±2.2%) Present study 
Spain 116–24,300 152–1170 
(Afonso-Olivares et 
al., 2017) 
Spain <LOD–1,65  
(Camacho-Muñoz et 
al., 2014) 
Italy 130–190 56.0–110 (Verlicchi et al., 2012) 
UK <4–346 <3.00–37.0 
(Kasprzyk-Hordern et 
al., 2009) 
UK n.d. 15.2–64.0 (Petrie et al., 2017) 
Asia China 100.6–7881.0 37.7–1712.7 (Zhang et al., 2018) 








Portugal 28.6 (±7.3%) n.d. Present study 
Spain 144–5140 50.0–872 
(Afonso-Olivares et 
al., 2017) 
Spain 800–4200  (Mendoza et al., 2015) 
Spain <LOD–33,400  
(Camacho-Muñoz et 
al., 2014) 
Italy 780–910 100–210 (Verlicchi et al., 2012) 
Greece n.d.–5899.9 n.d.–483.5 (Kosma et al., 2014) 
UK 400–3504 <2–703 
(Kasprzyk-Hordern et 
al., 2009) 
UK 3800 8920 (Nakada et al., 2017) 
UK 6985–20,398 3291–6412 (Petrie et al., 2017) 
America 
Mexico 825–4210 49–392 
(Rivera-Jaimes et al., 
2018) 
USA  11.0–41.0 (Nelson et al., 2011) 
Asia 
Vietnam 60.0–170 n.d. (Nguyen et al., 2018) 
Japan 30.0–430 10–90 (Suzuki et al., 2014) 







Salicylic acid Europe 
Portugal 1099 (±7.9%) 107 (±4.9%) Present study 
Spain <LOD–3295000  
(Camacho-Muñoz et 
al., 2014) 
Italy 210–1100 110–130 (Verlicchi et al., 2012) 






Greece <LOQ–89,133.5 n.d.–431.9 (Kosma et al., 2014) 
UK 1479–32,082 <1.00–497 
(Kasprzyk-Hordern et 
al., 2009) 
America Mexico 125–408 65–320 
(Rivera-Jaimes et al., 
2018) 




Portugal 402 (±7.2%) 283 (±4.0%) Present study 
Italy 10.0–330 70–180 (Verlicchi et al., 2012) 
UK 52.0–283.5 84.5–147.5 (Petrie et al., 2017) 
America USA  124–385 (Nelson et al., 2011) 
Clarithromycin 
Europe 
Portugal <MDL <MDL Present study 
Italy 110–780 260–310 (Verlicchi et al., 2012) 
Asia 
Korea 9.00–85.0  (Hong et al., 2015) 
China 374.4–661.4 1.20–342.6 (Zhang et al., 2018) 
Ciprofloxacin 
Europe 
Portugal 448 (±12%) 159 (±11%) Present study 
Spain 94.0–4.220 >MDL–89.0 
(Afonso-Olivares et 
al., 2017) 
Spain <LOQ–3260  
(Camacho-Muñoz et 
al., 2014) 
Italy 1100–3700 290–1100 (Verlicchi et al., 2012) 
Asia India 12,000–140,000 5000–58,000 (Archana et al., 2017) 
Australian Australia 1100 1300 
(Watkinson et al., 
2009) 






Australia 4600 720 
(Watkinson et al., 
2007) 
Australia 530 n.d. (Cardenas et al., 2016) 
Ofloxacin Europe 
Portugal <MDL 147 (±12%) Present study 
Spain 43.0–2280 <MQL–>MQL 
(Afonso-Olivares et 
al., 2017) 
Italy 450–2200 220–520 (Verlicchi et al., 2012) 
Sulfamethoxazole 
Europe 
Portugal 600 (±5.4%) n.d. Present study 
Spain 19.0–1150 n.d.–1520 
(Afonso-Olivares et 
al., 2017) 
Spain <LOQ–1030  
(Camacho-Muñoz et 
al., 2014) 
Italy 280–740 170–240 (Verlicchi et al., 2012) 
Greece n.d–2170.4 n.d.–72.9 (Kosma et al., 2014) 
UK 64.5–1154 23.0–188.8 (Petrie et al., 2017) 
America 
Mexico 775–2010 440–1215 
(Rivera-Jaimes et al., 
2018) 
USA 600–1500 1150–1550 (Gerrity et al., 2011) 
USA  18–265 (Nelson et al., 2011) 
Asia 
Japan 6.90–27.0 24.0–28.0 (Chang et al., 2008) 
Korea n.d.–229  (Hong et al., 2015) 
China 214–982 25.0–366 (Zhang et al., 2018) 
India <LOQ–690 n.d–420 (Subedi et al., 2017) 







Australia 3000 230 
(Watkinson et al., 
2009) 
Australia 500 720 
(Watkinson et al., 
2007) 
Australia 3570 260 (Cardenas et al., 2016) 
Trimethoprim 
Europe 
Portugal n.d. 24.2 (±3.8%) Present study 
Spain 60.0–452 n.d.–31.0 
(Afonso-Olivares et 
al., 2017) 
Spain <LOQ–500  
(Camacho-Muñoz et 
al., 2014) 
Italy 3.00–72.0 36.0–51.0 (Verlicchi et al., 2012) 
Greece <LOQ–180.3 n.d.–111.2 (Kosma et al., 2014) 
UK 931.5–2124 554.0–1104 (Petrie et al., 2017) 
America 
Mexico 125–790 135–395 
(Rivera-Jaimes et al., 
2018) 
USA 490–1100 50.0–200 (Gerrity et al., 2011) 
USA  <10.0–59.0 (Nelson et al., 2011) 
Asia 
Japan 14.0–42.0 11.0–26.0 (Chang et al., 2008) 
Korea 3.00–38.0  (Hong et al., 2015) 
China 11.2–423.2 4.3–427.8 (Zhang et al., 2018) 
India <LOQ–400 n.d.–25.0 (Subedi et al., 2017) 
Australian Australia 4300 250 
(Watkinson et al., 
2009) 






Australia 930 320 
(Watkinson et al., 
2007) 
Australia 2350 260 (Cardenas et al., 2016) 
Psychiatric drugs Carbamazepine 
Europe 
Portugal 820 (±1.9%) 1059 (±6.2%) Present study 
Spain 281–3030 11.0–1770 
(Afonso-Olivares et 
al., 2017) 
Spain <LOQ–180  
(Camacho-Muñoz et 
al., 2014) 
Italy 300–1170 280–440 (Verlicchi et al., 2012) 
Greece <LOQ–354.7 n.d.–416.8 (Kosma et al., 2014) 
Germany 150 140 
(Bahlmann et al., 
2014) 
Germany 660 (median) 740 (median) (Wick et al., 2009) 
Germany n.d. 2100 (Ternes, 1998) 
Germany  170–2700 (Brunsch et al., 2018) 
UK n.d–790 274–876 (Nakada et al., 2017) 
UK 168.6–367.0 134.7–175.8 (Petrie et al., 2017) 
America 
Mexico 85–380 165–476 
(Rivera-Jaimes et al., 
2018) 
USA 34.0–350 nd–62.0 (Yu et al., 2013) 
USA 24.8–50.9 33.7–111.2 
(Spongberg and 
Witter, 2008) 
USA 20–100 100–200 (Gerrity et al., 2011) 
USA  223–297 (Nelson et al., 2011) 







Vietnam 30.0–190 <LOQ–0.05 (Nguyen et al., 2018) 
Korea 43.0–127 40.0–74.0 (Behera et al., 2011) 
Korea 14.0–58.0  (Hong et al., 2015) 
China 62.7–2499 43.4–672.5 (Zhang et al., 2018) 
India 240–750 290–770 (Subedi et al., 2017) 
Australian 
Australia 1600 830 (Cardenas et al., 2016) 
Australia 589–685 685–702 (Roberts et al., 2016) 
Europe/Asia Turkey 6.35–135.6 <LOD–245.13 (Aydin et al., 2017) 
Citalopram Europe 
Portugal 149 (±1.6%) 148 (±0.68%) Present study 
UK 239.0–509.5 189.0–270.5 (Petrie et al., 2017) 
Demethylcitalopram Europe 
Portugal n.d. 364 (±7.7%) Present study 
UK 37.0–172.5 17.0–57.5 (Petrie et al., 2017) 
Fluoxetine 
Europe 
Portugal 78.0 (±2.6%) 57.5 (±7.1%) Present study 
Spain 77.0–207 63.0–72.0 
(Afonso-Olivares et 
al., 2017) 
Italy 55.0–190 10.0–63.0 (Verlicchi et al., 2012) 
UK 4.90–175.9 5.60–44.9 
(Baker and Kasprzyk-
Hordern, 2013) 
UK 36.0–436.5 33.0–66.5 (Petrie et al., 2017) 
Norway 0.400–2.40 n.d.–1.30 (Vasskog et al., 2006) 
America 
USA  18.0–22.0 (Nelson et al., 2011) 
Canada 16.0–26.0 6.60–20.0 
(Lajeunesse et al., 
2012) 






Australian Australia n.d.–51.1 n.d.–16.2 (Roberts et al., 2016) 
Europe/Asia Turkey <LOD–2.60 <LOD–2.70 (Aydin et al., 2017) 
Venlafaxine 
Europe 
Portugal 275 (±1.5%) 484 (±6.5%) Present study 
Spain 40–520 60–300 
(Gracia-Lor et al., 
2012) 
UK 28.8–446.1 21.4–285.1 
(Baker and Kasprzyk-
Hordern, 2013) 
UK 119.2–642.9 170.5–251.4 (Petrie et al., 2017) 
America 
USA n.d. <10.0–5500 (Writer et al., 2013) 
Canada 788–2987 600–2563 
(Lajeunesse et al., 
2012) 
Asia India n.d.–76.0 n.d–18.0 (Subedi et al., 2017) 
Australian 
Australia 100–100 511–736 (Roberts et al., 2016) 
Australia 2000 1450 (Cardenas et al., 2016) 
O-
Desmethylvenlafaxine 
Europe Portugal 865 2014 (±8.8%) Present study 
America Canada 345 330 
(Lajeunesse et al., 
2008) 
Lipid regulator and cholesterol 
lowering statin drugs 
Atorvastatin 
Europe 
Portugal 197 (±3.2%) n.d. Present study 
Italy <LOD–18.0 <LOD–10.0 (Verlicchi et al., 2012) 
UK 216.5–788.5 69.0–233.0 (Petrie et al., 2017) 
America USA 1560 240 (Ottmar et al., 2012) 
Asia India 110–690 <LOQ–510 (Subedi et al., 2017) 
Australian Australia 1000  (Cardenas et al., 2016) 
Gemfibrozil Europe Portugal 57.0 (±6.4%) 13.2 (±7.5%) Present study 






Spain 126–45,200 8.00–20,100 
(Afonso-Olivares et 
al., 2017) 
Spain 652–99,574 447–12,697 (Urtiaga et al., 2013) 
Spain <LOQ–58,300  
(Camacho-Muñoz et 
al., 2014) 
Greece n.d.–733.2 n.d.–230.9 (Kosma et al., 2014) 
America 
Mexico 20.0–225 20.0–380 
(Rivera-Jaimes et al., 
2018) 
USA  215–773 (Nelson et al., 2011) 
USA 3470–63,800 80.0–19,400 (Fang et al., 2012) 
Asia China 4.70–220.3 0.300–6.90 (Zhang et al., 2018) 
Australian Australia 1000  (Cardenas et al., 2016) 
Calcium channel blocker Diltiazem 
Europe Portugal <MDL <MDL Present study 
Europe/Asia Turkey 520–3300 n.d.–1120 (Muz et al., 2012) 
β-Blockers Propranolol Europe 
Portugal 320 (±9.4%) n.d. Present study 
Spain 54.0–695 n.d.–<MQL 
(Afonso-Olivares et 
al., 2017) 
Spain <LOQ–120  
(Camacho-Muñoz et 
al., 2014) 
Italy 14.0–45.0 13.0–26.0 (Verlicchi et al., 2012) 
UK 60.0–638 93.0–388 (Gardner et al., 2013) 
UK 83.1–269.7 60.9–102.7 (Petrie et al., 2017) 
UK n.d–29 1.00–1464 (Kay et al., 2017) 
Germany 40.0 (median) 40.0 (median) (Wick et al., 2009) 






America USA  n.d.–25 (Nelson et al., 2011) 
Asia 
China 3.40–60.9 1.90–17.2 (Zhang et al., 2018) 
Korea 4.00–19–0  (Hong et al., 2015) 
India 30–62 21.0–52.0 (Subedi et al., 2017) 
Australian 
Australia 18.1–151 36.8–75.8 (Roberts et al., 2016) 
Australia 130 60.0 (Cardenas et al., 2016) 
Stimulant, anorexics, anxiolytics, 
laxatives 
d,l-Norephedrine Europe 
Portugal 1013 (±0.20%) n.d. Present study 
UK n.d. n.d. 
(Kasprzyk-Hordern et 
al., 2010) 
UK 359.3 52.7 (Evans et al., 2015) 
UK 15.0–99.9 n.d. 
(Baker and Kasprzyk-
Hordern, 2013) 
UK n.d. n.d. (Petrie et al., 2017) 
Caffeine 
Europe 
Portugal 63,965 (±2.3%) n.d. Present study 
Spain 14,000–145,000 17.0–3260 
(Afonso-Olivares et 
al., 2017) 
Spain 360–72,400  
(Camacho-Muñoz et 
al., 2014) 
Greece n.d.–96,648.3 n.d.–1180.5 (Kosma et al., 2014) 
UK 1044.7150,413.6 148.4–34,198.3 
(Baker and Kasprzyk-
Hordern, 2013) 
UK 26,000–542,000 110–1370 (Nakada et al., 2017) 
UK 41,625–230,562 1125–18,688 (Petrie et al., 2017) 
America USA 500 to 320,000  (Conn et al., 2006) 







China 50,000  (Zhou et al., 2010) 
China 3793.6–39,665.6 15.8–1790.9 (Zhang et al., 2018) 
Vietnam 12,140–25,000 <LOQ–1600 (Nguyen et al., 2018) 




(Archana et al., 2017) 
India 16,000–120,000 810–4400 (Subedi et al., 2017) 
Pharmaceutical concentrations found in this study are discussed in the following 
subsections, and compared to the values reported in the literature in Table 2, where 
pharmaceuticals are presented by alphabetical order for the different therapeutic classes. 
For each compound, the results obtained in the different countries were grouped by 
continent. 
3.2.1. NSAIDs/analgesics 
NSAIDs/analgesics are a widely used therapeutic group not only by the Portuguese 
population but also worldwide. The Portuguese law defines NSAIDs/analgesics as 
prescription-only medicines or over-the counter pharmaceuticals, depending on the active 
ingredients and/or the dosages (Nunes et al., 2016). Literature refers that in countries 
where over-the-counter pharmaceuticals can be sold, NSAIDs/analgesics can be acquired 
outside of the pharmacies. Thus, the increase in NSAIDs/analgesics consumption and the 
decrease in professional counselling may pose a serious risk for a substantial increase in 
adverse effect occurrences in humans (Howard et al., 2007) and in the environment (He 
et al., 2017). 
As can be seen in Table SM6 (Supplementary material) and Table 2, diclofenac, one of 
the pharmaceuticals in the EU watch list, was detected in both matrices. In WWTP 
influents, seven of the found pharmaceuticals belonging to this group presented a 
concentration that varied from <MDL (ketoprofen) to 2838 ng/L (hydroxyibuprofen). 
High concentration values were noted for three compounds, namely: acetaminophen, 
hydroxyibuprofen, and salicylic acid, the last two compounds being metabolites. For the 
WWTP effluents, 5 pharmaceuticals were detected with concentrations ranging from 56.5 
(ketoprofen) to 1934 ng/L (diclofenac). 
These results are in agreement with the literature (Table 2) where Mendoza et al. (2015) 
stated that acetaminophen, naproxen, diclofenac, and ibuprofen were the compounds that 
contributed most to the total concentrations of pharmaceuticals measured in their study 
(Mendoza et al., 2015). In the study performed in 2017 by Gros et al., acetaminophen, 
ibuprofen and diclofenac, were also found in concentration levels of μg/L in WWTP 
matrices (Gros et al., 2017). Afonso-Olivares and collaborators detected diclofenac in the 
range of n.d. to 3.91 μg/L, ketoprofen in the range of 0.116 to 24.3 μg/L, naproxen in the 
range of 0.077 to 5.14 μg/L, and ibuprofen in the range of 0.021 to 56.3 μg/L (Afonso-
Olivares et al., 2017). The highest concentration reported by these authors was higher 
than the concentration found in the present study for ketoprofen, naproxen, and ibuprofen. 
Kasprzyk-Hordern et al. (2009) studied the fate of 55 emerging pollutants in two WWTPs 
in South Wales (UK) and reported an average acetaminophen concentration > 180 μg/L 
over a period of 5 months, demonstrating that the micropollutant concentrations were 
correlated with their usage/consumption patterns (Kasprzyk-Hordern et al., 2009). 
The highest concentrations of salicylic acid were measured in industrial wastewater, 
reaching levels up to 3295 μg/L (Camacho-Muñoz et al., 2014). 
3.2.2. Antibiotics 
Overuse and misuse of antibiotics can promote the development of antibiotic-resistant 
bacteria. Antibiotics have attracted increasing concern due to their high human and 
veterinary use. 
Sulfonamides, fluoroquinolones and macrolides were the three subclasses of antibiotics 
detected (Table SM6 (Supplementary material) and Table 2). Two of the three macrolides 
listed in the watch list were found either in effluent and influent samples. Concentrations 
in the range of <MDL (clarithromycin and ofloxacin) to 600 ng/L (sulfamethoxazole) in 
WWTP influents and in the range of <MDL (clarithromycin) to 283 ng/L (azithromycin) 
in WWTP effluents were obtained. Sulfamethoxazole and sulfapyridine (Table SM6, 
Supplementary material) were detected only in WWTP influent and trimethoprim was 
detected only in WWTP effluent. The highest concentration was observed for 
sulfamethoxazole (600 ng/L) in WWTP influents and azithromycin (283 ng/L) in WWTP 
effluents. As also reported by Rivera-Jaimes et al. (2018), sulfamethoxazole was found 
at higher levels compared to trimethoprim (Rivera-Jaimes et al., 2018). 
In literature, concentrations in the range of: n.d. to 398 ng/L for trimethoprim (Afonso-
Olivares et al., 2017; Kosma et al., 2014), >MQL to 2.28 μg/L for ofloxacin (Afonso-
Olivares et al., 2017), >MDL to 4.22 μg/L for ciprofloxacin (Afonso-Olivares et al., 
2017), and n.d. to 1.52 μg/L for sulfamethoxazole (Afonso-Olivares et al., 2017; Kosma 
et al., 2014) were observed (Table 2). 
3.2.3. Psychiatric drugs 
Psychiatric drugs are not completely metabolized by the human body and the unchanged 
parent compound, metabolites or conjugates are excreted (Heberer, 2002). 
Concentrations in the μg/L range were obtained for carbamazepine and O-
desmethylvenlafaxine in WWTP effluent (Table SM6 (Supplementary material) and 
Table 2). The lowest concentration was found for fluoxetine in WWTP influent and 
bupropion in WWTP effluent. Demethylcitalopram and bupropion (Table SM6, 
Supplementary Material) were detected only in WWTP effluents. Higher concentrations 
of carbamazepine, O-desmethylvenlafaxine, and venlafaxine were observed in WWTP 
effluent when compared with the WWTP influent. 
In Portugal, according to the regulatory pharmaceuticals Agency, INFARMED, only 
venlafaxine is authorized as an active substance. To our knowledge, O-
desmethylvenlafaxine is not an authorized pharmaceutical in Portugal, despite its use as 
an active substance is authorized in other countries. Therefore, in this study, it is assumed 
that the presence of O-desmethylvenlafaxine in the samples results from being the main 
venlafaxine metabolite. 
Almost all the psychiatric drugs were detected at similar or higher concentrations in 
WWTP effluent than in WWTP influent (Table SM6, Supplementary material). This is in 
agreement with previously published data, where low or no removal of the psychiatric 
drugs carbamazepine, venlafaxine, and fluoxetine were described (Paíga et al., 2016). 
Similar results were observed in other studies (Gros et al., 2007; Kosma et al., 2014; 
Papageorgiou et al., 2016; Verlicchi et al., 2012) (Table 2). 
Pharmaceuticals excreted as conjugates can be cleaved by enzymes during the wastewater 
treatment process, converting them again in the parent compound form (Bahlmann et al., 
2014). The gradual release of psychiatric drugs adsorbed onto sludge during biological 
treatment, can also lead to an increase of these compounds in the WWTP effluents and, 
consequently, to a negative removal rate (Jelic et al., 2011). 
Carbamazepine, diazepam, fluoxetine, lorazepam, and paroxetine are psychiatric drugs 
commonly detected in the environment (Aydin et al., 2017) (Table 2). Concentrations of 
carbamazepine in WWTP samples in different developed countries, mostly from Europe, 
averaged the μg/L levels (Verlicchi et al., 2012). In other continents, concentrations of 
carbamazepine of hundreds of ng/L were also found in recent years (Table 2). In the study 
conducted by Afonso-Olivares et al. (2017), concentrations in the range of n.d to 
0.207 μg/L for fluoxetine and 0.011 to 3.03 μg/L for carbamazepine were obtained. 
Venlafaxine has been detected in concentrations in the μg/L range in the USA, Canada 
and Australia (Table 2). 
3.2.4. Stimulants 
Caffeine was included in the study because it is a central nervous system stimulant 
(Nehlig et al., 1992). Caffeine is often the compound reported with the highest frequency 
and concentration (Seiler et al., 1999; Spongberg et al., 2011) in similar studies and has 
previously been used as an indicator of anthropogenic contamination (Buerge et al., 2003; 
Daneshvar et al., 2012; Paíga and Delerue-Matos, 2017; Seiler et al., 1999). The abundant 
presence of caffeine is associated with the high consumption of coffee, tea, and soft drinks 
as well as the disposal of these items (Luo et al., 2014). 
The high concentration (63.97 μg/L in WWTP influent) obtained in the present study 
(Table SM6, Supplementary material), is in accordance with other studies reported in the 
literature (Table 2). Caffeine was detected approximately at 50 μg/L in the raw sewage in 
three WWTPs in China (Zhou et al., 2010), between 0.012 and 145 μg/L in the study 
conducted by Afonso-Olivares et al. (2017), and in the range of ˂0.5 to 320 μg/L in a 
screening study in the U.S.A. (Conn et al., 2006). In Costa Rica, high concentrations were 
observed not only for caffeine, but also for pharmaceuticals (Spongberg et al., 2011). 
Caffeine had the maximum concentration of 1.1 mg/L, possibly due to coffee bean 
production facilities upstream. Pharmaceuticals were detected at alarmingly high levels 
with maximum concentrations of 74, 37, 17, 13, and 10 μg/L for doxycycline, ibuprofen, 
gemfibrozil, acetaminophen, and ketoprofen (Spongberg et al., 2011). Caffeine had the 
highest observed concentration of 373 μg/L in a study conducted in India (Archana et al., 
2017). 
3.2.5. Other therapeutic classes 
The remaining pharmaceuticals detected (Table SM6, Supplementary material), 
belonging to the lipid regulator and cholesterol lowering statin drugs (atorvastatin and 
gemfibrozil), presented a concentration of 57.0 ng/L for gemfibrozil and 197 ng/L for 
atorvastatin in WWTP influents and 13.2 ng/L for gemfibrozil in WWTP effluents. 
Diltiazem (calcium channel blocker) was detected below the MDL for both WWTP 
matrices. Propranolol and d,l-norephedrine were both detected only in WWTP influent 
with a concentration of 320 ng/L and 1.013 μg/L (Table SM6, Supplementary material). 
A literature review (Table 2) showed that propranolol was found in Spain in levels of 
<MQL to 695 ng/L (Afonso-Olivares et al., 2017; Urtiaga et al., 2013), and between 60 
to 638 ng/L in WWTP influents and 93 to 388 ng/L in WWTP effluents in the UK 
(Gardner et al., 2013). Gemfibrozil was found at concentration values between 0.652 and 
99.574 μg/L in WWTP influents and 0.447 and 12.697 μg/L in WWTP effluents in Spain 
(Urtiaga et al., 2013) and between 3.47 and 63.8 μg/L in WWTP influents and 0.08 and 
19.4 μg/L in WWTP effluents in Texas (Fang et al., 2012). Atorvastatin was found in the 
USA with a concentration of 1.56 and 0.24 μg/L for WWTP influents and effluents 
(Ottmar et al., 2012). In 2012, diltiazem was detected in almost of all WWTP samples. 
Thus, a concentration between 0.52 and 3.30 μg/L in WWTP influents and in the range 
of n.d. to 1.12 μg/L in WWTP effluents was achieved in Turkey (Muz et al., 2012). In the 
UK, norephedrine was neither detected in WWTP influents (Kasprzyk-Hordern et al., 
2010) nor in WWTP effluents (Baker and Kasprzyk-Hordern, 2013; Kasprzyk-Hordern 
et al., 2010). However, it was detected in other studies in UK at 359.3 ng/L in WWTP 
influents and 52.7 ng/L for WWTP effluents (Evans et al., 2015), and from 15.0 to 
99.9 ng/L in WWTP influents (Baker and Kasprzyk-Hordern, 2013). To the best of our 
knowledge, this was the first time that norephedrine was found in WWTP samples in 
Portugal. 
3.2.6. Metabolites and their parent pharmaceuticals 
Studies have focused on the occurrence, fate, behavior, distribution, and toxicity of 
pharmaceuticals in wastewater influent and effluent (Gros et al., 2007), sludge 
(Radjenović et al., 2009), surface water (Rivera-Jaimes et al., 2018), and sediment and 
soil (Diaz-Cruz et al., 2003; Koba et al., 2018). Pharmaceuticals are released into the 
environment either as parent compound and as active/inactive metabolites (Christensen, 
1998). Therefore, it is important to underline that not only the parent compound should 
be the target of the studies but also the transformation products and metabolites. 
Moreover, in 2017, Yin et al. mentioned that transformation products and metabolites are 
detected at higher concentrations than their parent compounds (Yin et al., 2017). 
A total of eighteen compounds were analysed including seven pharmaceuticals, their 
transformation products, and their metabolites. The concentrations (ng/L) obtained are 
shown in Fig. SM4 (Supplementary material). 
Concentrations ranged from n.d. to 2838 ng/L (hydroxyibuprofen) for WWTP influents 
and n.d. to 2014 ng/L (O-desmethylvenlafaxine) for WWTP effluents. 
Carboxyibuprofen, acetylsalicylic acid, 10,11-epoxi carbamazepine, norfluoxetine, 
sertraline, norsertraline, citalopram propionic acid, citalopram N-oxide, citalopram 
didemethyl were not detected either in the WWTP influents and effluents. Only the parent 
compounds, carbamazepine and fluoxetine, were detected in both WWTP matrices. 
Carbamazepine was found with concentrations of 820 ng/L for WWTP influent, and 
1059 ng/L for WWTP effluent and fluoxetine with 78 ng/L for WWTP influent, and 
57 ng/L for WWTP effluent. Similar to the achievements in this study, Weston et al. 
(2003) reported fluoxetine levels up to 540 ng/L in two WWTP effluents and 
norfluoxetine was not detected (Weston et al., 2003). 
Comparing the levels found for ibuprofen and its metabolites, a higher concentration was 
obtained for hydroxyibuprofen when compared with ibuprofen in both WWTP matrices. 
The highest concentration was observed for hydroxyibuprofen in WWTP influents 
(2838 ng/L) (Table SM6, Supplementary Material) and carboxyibuprofen was not 
detected. 
95% of ibuprofen is excreted in the urine, of which 35% is excreted as hydroxyibuprofen 
(15% free, 20% conjugated), 51% as carboxyibuprofen (42% free, 9% conjugated), and 
9% as ibuprofen (1% free, 8% conjugated) (Ternes et al., 2004). In the environment, 
hydroxyibuprofen was detected as the main component related to ibuprofen. It was also 
noted that ibuprofen metabolites can also be formed during the biodegradation of 
ibuprofen, but as hydroxyibuprofen is a more stable compound, showing lower removal 
percentages than carboxyibuprofen (Ferrando-Climent et al., 2012), it is probable that 
hydroxyibuprofen would be present at higher concentrations than ibuprofen (Ferrando-
Climent et al., 2012), as was reported in the present study. 
The non-detection of acetylsalicylic acid can be related to its hydrolysis. Acetylsalicylic 
acid, undergoes hydrolysis with the resultant transformation products being salicylic acid 
and acetic acid (Farrell, 2017). Therefore, salicylic acid in the environmental would be 
detected more frequently and with higher levels than acetylsalicylic acid. Concentrations 
of 1099 and 107 ng/L for WWTP influents and WWTP effluents were reached in the 
present study. 
Venlafaxine undergoes extensive first-pass metabolism and <5% of the parent 
pharmaceutical is excreted in the urine. Most of it is metabolized in the liver to a major 
metabolite, O-desmethylvenlafaxine, and two minor, less active metabolites. In line with 
our results, Lajeunesse et al. (2008) showed that higher concentrations of O-
desmethylvenlafaxine were determined in raw sewage and effluent in Montreal WWTP, 
with concentrations of 345 ng/L and 330 ng/L, respectively, approximately 1.5 times 
higher than that of the parent compound (Lajeunesse et al., 2008). The results found in 
the WWTP under study reveal concentrations between 275 and 484 ng/L for venlafaxine 
and between 865 and 2014 ng/L for O-desmethylvenlafaxine in WWTP influent and 
effluent samples, respectively. 
Hence, some transformation products and/or metabolites are not completely removed in 
WWTPs, and together with their parent compounds will be simultaneously discharged 
through WWTP effluent and enter in surface water. Therefore, monitoring studies of 
pharmaceuticals in the environment should cover not only the detection of parent 
compounds, but also their transformation products and metabolites, considering the high 
concentrations found in several reported studies. 
3.3. Hourly pharmaceutical determination in WWTP influent and effluent 
WWTP influents and effluents were collected hourly for one day. A total of 24 samples 
for influent and 24 samples for effluent were collected, extracted, and analysed. Thirty-
eight and twenty-nine pharmaceuticals were detected in at least one sample in WWTP 
influents and effluents (Fig. SM5, Supplementary material). Minimum, maximum, 
average, number of times that a pharmaceutical is detected and detection frequency for 
each detected pharmaceutical in WWTP effluent are shown in Table 3. 
Table 3. Minimum, maximum, and average concentration, number of times that a 
pharmaceutical is detected and detection frequency for each detected pharmaceutical in 
WWTP influent and effluent samples. 
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als 

















































Azithromycin n.d. 453 283 11 45.8 207 316 257 24 100 
Acetaminoph
en 
n.d. 728 477 7 29.2 n.d. n.d. –   
Atorvastatin n.d. 325 238 9 37.5 n.d. n.d. –   
Bupropion n.d. <MDL a 4 16.7 n.d. <MDL a 16 66.7 
Caffeine 6527 84,265 
55,10
2 
24 100 n.d. n.d. –   
Carbamazepi
ne 
462 1339 689 24 100.0 790 1427 1107 24 100 
Ciprofloxacin n.d. 684 579 5 20.8 n.d. 285 250 2 8.3 
Citalopram n.d. 200 167 13 54.2 n.d. 173 147 18 75.0 
Citalopram 
propionic acid 
n.d. <MDL a 2 8.3 n.d. <MDL a 1 4.2 
Clarithromyci
n 
n.d. <MDL a 13 54.2 n.d. <MDL a 18 75.0 
Demethylcital
opram 




459 1061 786 24 100 991 1876 1340 24 100 
Diazepam n.d. 56 b 1 4.2 n.d. 35 b 1 4.2 
Diclofenac 41 2778 373 24 100 84 2922 1412 24 100 
Diltiazem n.d. <MDL a 13 54.2 n.d. <MDL a 22 91.7 




n.d. <MDL a 1 4.2 n.d. <MDL a 1 4.2 
Fluoxetine 49 92 76 24 100 n.d. 79 67 23 95.8 
Gemfibrozil 17 184 59 24 100 13 36 27 24 100 
Hydroxyibup
rofen 
1812 22,909 7046 24 100 <MDL 577 269 24 100 
Ibuprofen 127 7681 689 24 100 80 358 196 24 100 
Ketoprofen n.d. <MDL a 19 79.2 n.d. n.d. –   
Lomefloxacin n.d. n.d. –   n.d. <MDL a 1 4.2 
Lorazepam n.d. n.d. –   n.d. 91 74 2 8.3 
Pharmaceutic
als 

















































Moxifloxacin n.d. 324 290 2 8.3 n.d. n.d. –   
Naproxen n.d. 376 80 21 87.5 <MDL 122 66 24 100 
d,l-
Norephedrine 
n.d. 2595 991 4 16.7 n.d. n.d. –   
Norsertraline n.d. n.d. –   n.d. 228 b 1 4.2 
Ofloxacin n.d. 39 b 1 4.2 n.d. 233 174 9 37.5 
Propranolol n.d. 528 344 14 58.3 n.d. n.d. –   
Salicylic acid n.d. 7014 1099 12 50.0 n.d. 172 115 16 66.7 
Sertraline n.d. 172 163 3 12.5 n.d. 100 96 5 20.8 
Simvastatin n.d. 485 b 1 4.2 n.d. n.d. –   
Sulfadiazine n.d. <MDL a 1 4.2 n.d. n.d. –   
Sulfamethizol
e 
83 83 .b 1 4.2 n.d. n.d. –   
Sulfamethoxa
zole 
229 1117 489 13 54.2 n.d. 114 57 4 16.7 
Sulfapyridine n.d. 1442 576 14 58.3 n.d. 36 35 3 12.5 
Sulfathiazole 220 220 b 1 4.2 n.d. n.d. –   
Trazodone n.d. 504 294 19 79.2 155 234 191 24 100 
Trimethopri
m 
n.d. <MDL a 1 4.2 n.d. 108 62 6 25.0 
Venlafaxine 220 363 285 24 100 411 543 486 24 100 
Pharmaceuticals organized in the table by alphabetic order. 
a-Average was not performed due to the minimum value (n.d.) and maximum value 
(<MDL). 
b-Pharmaceutical was detected in one sample of the 24 samples. 
Diclofenac, ibuprofen, hydroxyibuprofen, carbamazepine, fluoxetine, venlafaxine, O-
desmethylvenlafaxine, and gemfibrozil were the pharmaceuticals with detection 
frequency equal to 100% in both matrices. The pharmaceuticals only detected in WWTP 
influents were: caffeine (100%), naproxen (88%), propranolol (58%), azithromycin 
(46%), atorvastatin (38%), acetaminophen (29%), bupropion (17%), norephedrine (17%), 
moxifloxacin (8%), being enrofloxacin, ofloxacin, sulfadiazine, sulfathiazole, 
sulfamethizole, demethylcitalopram, diazepam, simvastatin the pharmaceuticals with the 
lowest detection frequency (4%). Nonetheless, azithromycin (100%), 
demethylcitalopram (75%), bupropion (67%), ofloxacin (38%), lorazepam (8%), 
lomefloxacin (4%), norsertraline (4%), and diazepam (4%) were the pharmaceuticals only 
detected in WWTP effluents. The remaining pharmaceuticals were detected in both 
matrices. However, higher detection frequencies were achieved in WWTP influents when 
compared with WWTP effluents for: fluoxetine (100% vs. 96%), sulfapyridine (58% vs. 
13%), sulfamethoxazole (54% vs. 17%), ciprofloxacin (21% vs. 8%), and citalopram 
propionic acid (8% vs.4%), while higher detection frequencies were found in WWTP 
effluents when compared with WWTP influents for: ketoprofen (100% vs. 79%), 
trazodone (100% vs. 79%), clarithromycin (75% vs. 54%), citalopram (75% vs. 54%), 
diltiazem (92% vs. 54%), salicylic acid (67% vs.5 0%), sertraline (21% vs. 13%), and 
trimethoprim (25% vs. 4%). For 10,11-epoxi carbamazepine, its presence was detected 
only in one sample of WWTP influent and effluent, and 4% of detection frequency was 
found. 
Regarding the WWTP influents, the analysis of the individual pharmaceutical 
concentrations obtained for each sampling hour, and the total concentration considering 
all pharmaceuticals was performed with the objective to check one pattern of the 
pharmaceuticals consumption. For WWTP effluents, only the total concentration was 
analysed for each sampling hour, since the concentration achieved in the WWTP effluents 
depends not only on the pharmaceutical consumption but also on the efficiency of the 
WWTP treatment. In the WWTP effluent, the objective was to verify the total 
concentration of pharmaceuticals that is released to the environment. Thus, in Fig. 2, the 
obtained concentration (ng/L) versus collection hour of the WWTP influent for each 
pharmaceutical, is presented. 
 
Fig. 2. Figure SM8-concentration (ng/L) versus hourly WWTP influent collection for the 
detected pharmaceuticals. 
There were some pharmaceuticals only detected in one sample, or with concentrations 
below the MDL and thereby the bar graph was not plotted. These pharmaceuticals were: 
ketoprofen (concentration range from n.d to <MDL), enrofloxacin (one sample detected: 
359 ng/L at 11 h), ofloxacin (one sample detected: 39 ng/L at 16 h), moxifloxacin (two 
samples detected: 324 ng/L (9 h) and 256 ng/L (12 h)), trimethoprim (concentration range 
from n.d to <MDL), sulfadiazine (concentration range from n.d to <MDL), sulfathiazole 
(one sample detected: 220 ng/L at 19 h), sulfamethizole (one sample detected: 83 ng/L at 
19 h), clarithromycin (range from n.d to <MDL), 10,11-epoxi carbamazepine 
(concentration range from n.d to <MDL), sertraline (three samples detected: 172 ng/L 
(23 h), 152 ng/L (04 h), and 164 ng/L (13 h)), citalopram propionic acid (concentration 
range from n.d to <MDL), demethylcitalopram (one sample detected: 253 ng/L at 22 h), 
diazepam (one sample detected: 56 ng/L at 24 h), bupropion (concentration range from 
n.d to <MDL), simvastatin (one sample detected: 485 ng/L at 21 h), and diltiazem 
(concentration range from n.d to <MDL). 
For NSAIDS/analgesics, the highest concentration peak was achieved at: 16, 18, 20 and 
01 h for acetaminophen, 10 h for diclofenac, 12 h for ibuprofen, 17, 18, 21, and 22 h for 
hydroxyibuprofen, 12 and 18 h for naproxen, and 15 and 16 h for salicylic acid. 
Diclofenac, ibuprofen, and hydroxyibuprofen were detected in all samples. For 
NSAIDs/analgesics, it could be seen that, diclofenac, ibuprofen and naproxen had the 
highest concentration in the end of the morning, salicylic acid in the middle of afternoon, 
hydroxyibuprofen between the end of the afternoon and the beginning of the night, and 
acetaminophen had several maxima but always in afternoon and at night, no values were 
found in the morning. 
For the antibiotics group, ciprofloxacin, sulfapyridine, sulfamethoxazole, and 
azithromycin were the antibiotics present in the bar charts in the Fig. 2. It is estimated 
that 30–90% of an administered dose of most antibiotics, human and veterinary, may be 
excreted as active substances (Chen et al., 2006). Ciprofloxacin was detected only in 21% 
of the samples: (i) in the middle of the afternoon (16 h), (ii) at the beginning of the night 
(20 and 21 h), and (iii) during the night at 04 and 06 h, respectively. The concentrations 
obtained in these five points were very similar. For the other antibiotics, there is a 
different pattern for each antibiotic. More samples were detected between 01 and 08 h for 
sulfamethoxazole, between 08 and 13 h for azithromycin, and between 18 and 23 h for 
sulfapyridine. From 13 to 18 h, there were not many samples detected. However, the 
concentration of ciprofloxacin, sulfamethoxazole and azithromycin reached higher values 
in that period of time and the highest concentration found for sulfapyridine was observed 
at 11 h. The administration of an antibiotic depends largely on the clinical picture, the 
condition of the patient, and the availability (Enenkel and Stille, 1988). It is important to 
highlight that a pattern could not be noticed in the results due to the different dosage, time 
of administration, and type of antibiotic used for each disease. 
According to literature, and the studies on the hourly variation of pharmaceuticals in 
WWTPs influents, several factors can contribute to these variations. Some of the most 
important are related to pharmaceuticals therapeutic class, posology and dosages. For 
instance, for antibiotics, Coutu et al. (2013) found a peak concentration in the morning 
and a second peak approximately 12 h later, which is in agreement with the typical 
patterns of consumption for some of these compounds. According to Zhang et al. (2018) 
the diurnal variations of antibiotics concentrations showed a very good consistency with 
the possible consumption timing and the citizens' movement between residence and 
working areas. The different hourly variation observed by Camacho-Muñoz et al. (2014) 
was found to be dependent on the pharmaceutical therapeutic group and the urban or 
industrial source. These authors report pharmaceutical concentrations during a 24 h 
period in accordance with their consumption and excretion patterns (Camacho-Muñoz et 
al., 2014). Regarding to other therapeutic families, the concentrations seem to be more 
consistent over time, according to some authors (Kay et al., 2017; Petrie et al., 2017), 
while for others the exact reason for the observed variability is unclear and further 
information on pharmacokinetics and consumer behavior would be necessary in order to 
give a definitive explanation (Gerrity et al., 2011; Hong et al., 2015; Nelson et al., 2011). 
Weather conditions can also influence hourly concentrations, as after heavy rainfall 
events, a decrease in pharmaceuticals concentration was observed. Dilution effects due to 
the increase in wastewater flowrates related to working hours or in the beginning/end of 
the day may also explain a decrease in the concentrations in particular moments of the 
day (Brunsch et al., 2018; Hong et al., 2015). The physicochemical properties of the 
compounds along with the chemical conditions found between the households and the 
WWTPs can also contribute to distinct diurnal variations for different compounds. 
From OECD (Organisation for Economic Co-operation and Development) Health 
Statistics 2017 (OECD, 2017), psychiatric drugs consumption increased twice in most 
countries between 2000 and 2015. Long-term use of psychiatric drugs, the constant 
release to the environment, and their persistency results in the detection of psychiatric 
drugs in all the analysed samples. For this group including carbamazepine and fluoxetine 
(Fig. 2) the obtained concentration was very similar, with exception of carbamazepine 
that had the highest peak at 20 h and at 11 h for trazodone. Carbamazepine, fluoxetine, 
venlafaxine, and O-desmethylvenlafaxine had 100% detection frequency and the highest 
concentration for the psychiatric drugs was noticed for the metabolite of venlafaxine. 
Finally, propranolol, gemfibrozil, atorvastatin, caffeine, and norephedrine were also 
detected. For propranolol, most of the samples were grouped between 20 and 06 h of the 
morning. Caffeine and gemfibrozil had 100% of detection frequency. The highest 
concentrations of gemfibrozil were observed at 08 h and 09 h and for propranolol about 
1 h earlier, which is in accordance with the findings of Camacho-Muñoz et al. (2014). 
The highest values obtained for caffeine were between 21 and 09 h. In Portugal, the 
consumption of coffee is a generalized practice throughout the day, what may explain 
these results. Fewer samples were detected in the case of atorvastatin and norephedrine. 
The highest value was observed at 20 h for atorvastatin and 01 and 11 h for norephedrine. 
In the following paragraphs, a discussion of the results for WWTP influents and effluents 
samples are performed, not for each pharmaceutical as was done in the previous 
paragraphs for WWTP influents, but for all pharmaceuticals that are detected in that 
specific sampling hour. Thus, the total concentration found for each sampling hour and 
for each type of WWTP sample is shown in Fig. 3. Due to the high concentration of 
caffeine found in the WWTP influents, it was decided to exclude it to avoid concealing 
the total concentration. 
 
Fig. 3. Radar chart of the total concentration for all detected pharmaceuticals (ng/L) in 
each sampling hour. 
Analysing each radar graph, it could be observed in the WWTP influent that the total 
concentration of detected pharmaceuticals is higher between 15 and 22 h and lowest in 
the period from 23 to 10 h in the morning. The total concentration starts to increase again 
until 12 h and then decreases at 13 h. In the WWTP effluent, the total concentration varies 
little throughout the sampling hours. 
Fast-target analysis and hourly variation of 60 pharmaceuticals in wastewater using 
UPLC-High resolution mass spectrometry was the study of Hong et al. (2015). Of the 
target pharmaceuticals in wastewater of a sewage-treatment plant analysed on an hourly 
basis, only 17 compounds were detected, and others were lower than the method detection 
limits. Concentration profiles of acetaminophen, caffeine, acetylsalicylic acid, 
chlorphenylamine, diclofenac, and mefenamic acid showed a significant decrease at 8 h 
due to dilution of high wastewater flow. The authors stated that the reason for the hourly 
variation of the remaining pharmaceuticals is unclear, which is likely due to their varying 
source and intermittent consumption (Hong et al., 2015). 
3.4. Environmental risk characterization 
Due to the high number of pharmaceuticals, only the database of the ECOSAR (U.S. EPA 
Ecological Structure Activity Relationships) was consulted. The pharmaceuticals were 
input by their CAS number. If RQ > 1, harmful effects could be expected due to the 
presence of the pollutant in water. On the contrary, if RQ < 0.1, the environmental risk is 
low (Ccanccapa et al., 2016). 
In order to ensure maximum protection, when the analytes were detected in the samples 
but the concentration was below either MDL or MQL, half of reported MQL was used as 
MEC to consider the worst-case scenario (Mendoza et al., 2015). Maximum measured 
concentration (ng/L), acute toxicity data (EC50/LC50) for all pharmaceuticals on fish, 
Daphnia magna, and algae, and the estimated RQs are presented in Table SM7 
(Supplementary material). 
RQs were calculated for 60 pharmaceuticals since no information was obtained for the 
remaining. Seven pharmaceuticals in WWTP influents and three pharmaceuticals in 
WWTP effluents present an RQs higher than 1. Carbamazepine, fluoxetine, and sertraline 
were the common pharmaceuticals with RQ > 1 in both WWTP matrices and atorvastatin, 
caffeine, simvastatin, and trazodone the pharmaceuticals with an RQ > 1 only in WWTP 
influents. Atorvastatin was the pharmaceutical with an RQ > 1 in the three trophic levels 
in the WWTP influent. The highest RQ value was observed for the stimulant caffeine in 
algae (WWTP influent). 
For the pharmaceuticals that showed an RQ > 1, it is important to highlight that four out 
of seven pharmaceuticals in WWTP influents and three out of three pharmaceuticals in 
WWTP effluents belong to the group of psychiatric drugs. Two lipid regulator and 
cholesterol lowering statin drugs (atorvastatin and simvastatin) and the stimulant 
(caffeine) were the other pharmaceuticals with an RQ > 1 in WWTP influents. 
Pharmaceuticals commonly prescribed to treat depression can affect aquatic insects, 
amphibians, and fishes (Richmond et al., 2016). Fluoxetine, sertraline, and their 
metabolites can bioaccumulate up to 1 μg/kg of fish in the brain, liver, and muscle tissue 
in several species (Brooks et al., 2003; Chu and Metcalfe, 2007). Conners et al. mentioned 
that fluoxetine and sertraline reduced the growth rates of tadpoles (Conners et al., 2009). 
Moreover, fluoxetine changed burrowing behavior of the freshwater bivalve at 22.3 μg/L 
(Hazelton et al., 2014) and induced spawning in zebra mussels at low concentrations 
(Fong, 1998). Citalopram induced foot detachment in freshwater gastropods at 405 pg/L 
and 4.05 μg/L (Fong and Hoy, 2012). The alga Pseudokirchneriella subcapitata showed 
to be more sensitive to citalopram and fluoxetine when compared to Daphnia magna 
(Christensen et al., 2007). Algae developed cell deformities when exposed to 13.6 and 
27.2 μg/L of fluoxetine (Brooks et al., 2003). One of the most commonly used 
benzodiazepines, diazepam, has been shown to increase activity in zebrafish (Oggier et 
al., 2010) and pumpkinseed sunfish (Brandão et al., 2013) at μg/L concentrations, and 
exposure to mg/L of diazepam increased boldness in larval zebrafish (Richendrfer et al., 
2012). Psychiatric drugs have been shown to reduce territorial aggression in coral reef 
fish (Perreault et al., 2003) and locomotion and aggression in Siamese fighting fish 
(Kohlert et al., 2012). 
Many toxicological studies have been conducted in order to assess the effects of 
psychiatric drugs but mainly referring to acute toxicity, using pharmaceuticals 
concentrations that are several orders of magnitude higher than the ones that are found in 
natural environments. Therefore, there is the need for further research on long term effects 
(chronic toxicity), by subjecting the test organisms to pharmaceuticals levels found in the 
environment, and particularly, when several different active substances are present 
concomitantly at the μg/L level. 
4. Conclusions 
The overarching goal of this study was the evaluation of the presence of 83 
pharmaceuticals belonging to different therapeutic classes, namely: non-steroidal anti-
inflammatory drugs, analgesics, antibiotics, anorectics, anxiolytics, laxatives, antidiabetic 
drug, antipsychotic, calcium channel blocker, β-blockers, fibrate lipid lowering agent, 
stimulants, lipid regulator and cholesterol lowering statin drugs, proton pump inhibitor, 
and psychiatric drugs in WWTP influent and effluent samples of one WWTP in Leiria 
(Portugal). Two WWTP influent and effluent samplings were performed, involving the 
sampling hourly in one day and its composites samples. 
The average recovery of pharmaceuticals was around 74.9% and 76.9% for WWTP 
effluent and influent samples. Recoveries above 75% were achieved for the majority of 
the studied pharmaceuticals. Therefore, STRATA-X cartridge and sample adjusted to 
pH 2 shows a good choice for the extraction of the selected pharmaceuticals. 
In the composite WWTP samples, most of pharmaceuticals detected belonging to the 
NSAIDs/analgesic, antibiotics, and psychiatric drugs. Higher concentrations were noticed 
for acetaminophen, hydroxyibuprofen, and salicylic acid in WWTP influent and 
diclofenac in WWTP effluents. Diclofenac, listed in the watch list, was detected in both 
matrices. Due to high human and veterinary use of antibiotics, concern and studies by the 
scientific community have been increasing. Two of the three macrolides listed in the 
watch list were found either in effluent and influent samples. Concentration obtained in 
antibiotics were between <MDL (clarithromycin and ofloxacin) to 600 ng/L 
(sulfamethoxazole) in WWTP influent and between <MDL (clarithromycin) to 283 ng/L 
(azithromycin) in WWTP effluent. Concentrations in the μg/L range were reached for 
carbamazepine and O-desmethylvenlafaxine in WWTP effluent. It is important to 
highlight that psychiatric drugs concentration in effluents were or higher or similar to the 
concentrations found in WWTP influent. The highest concentration obtained in the 
present study was found to caffeine. The obtained result is in line with other studies 
reported in literature. Atorvastatin and propranolol in WWTP influent and gemfibrozil 
and diltiazem in both WWTP matrices were found at concentration in the ng/L level. 
Finally, d,l-norephedrine was detected at μg/L in WWTP influent. 
One of the important points of our study was not only monitor pharmaceuticals but also 
monitor its transformation products and its metabolites. Thus, a total of eighteen 
compounds among which, pharmaceuticals, transformation products, metabolites were 
analysed. Hydroxyibuprofen, salicylic acid, and O-desmethylvenlafaxine were found in 
both matrices. Concentration in μg/L were reached for hydroxyibuprofen and salicylic 
acid in WWTP influent and for O-desmethylvenlafaxine in WWTP effluents. 
Demethylcitalopram was found in WWTP effluent with 364 ng/L. 
The main objective of the study proposed by the authors was to monitor the 83 compounds 
in samples collected hourly. Twenty-four samples were collected in the WWTP influents 
and effluents and after extracted and analysed in the UHPLC-MS/MS. 45.8 and 34.9% of 
the pharmaceuticals, more precisely 38 and 29 pharmaceuticals were detected in at least 
one WWTP sample in influents and effluents. The highest total concentration was reached 
between 15 and 22 h and lowest total concentration was found in the period from 23 to 
10 h in the morning in the WWTP influents. In the other hand, no evidence highs and 
lows total concentrations are highlighted in WWTP effluents. The concentration over the 
analysed hours is very consistent and it could not be possible to define one profile for the 
total concentration. 
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